The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Recruiting now

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Phase 2 · 332 people · 1 site in United States · Recruiting now

August 8, 2026
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Phase 1 · randomised · 1,394 people · 122 sites in 13 countries · Recruiting now

August 8, 2026
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 2 · 1,130 people · 32 sites in United States · Recruiting now

August 8, 2026
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Phase 2 · 180 people · 41 sites in 8 countries · Recruiting now

August 8, 2026
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Phase 2 · 40 people · 7 sites in United States · Recruiting now

August 8, 2026
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 2 · 336 people · 15 sites in 3 countries · Recruiting now

August 8, 2026
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Phase 2 · 252 people · 8 sites in 3 countries · Recruiting now

August 8, 2026
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2 · 37 people · 7 sites in United States · Recruiting now

August 8, 2026
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Phase 2 · randomised · 330 people · 6 sites in United States · Recruiting now

August 8, 2026
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Phase 2 · 26 people · 1 site in United States · Recruiting now

August 8, 2026